CAPAD(Capecitabine)
Therapeutic class: Nucleoside metabolic inhibitor
- Adjuvant Colon Cancer – Patients with Dukes’ C colon cancer
- Metastatic Colorectal Cancer – First-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred
- Metastatic Breast Cancer – In combination with docetaxel after failure of prior anthracycline containing therapy – As monotherapy in patients resistant to both paclitaxel and an anthracycline-containing regimen
500 mg Tablets
500 mg:- A strip of 10 tablets- 20°C to 25°C (68°F to 77°F), Shelf Life: 2 Years
- As directed by physician
